NCT00565279View on ClinicalTrials.gov

Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis

PHASE3CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2008

Conditions

Seborrheic Dermatitis

Interventions

DRUG

ASF1057

Twice daily, topical

DRUG

ASF1057

Twice daily, Topical

Sponsors

Lead Sponsor

Astion Pharma A/S

All Listed Sponsors

lead

Astion Pharma A/S

INDUSTRY

NCT00565279 - Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis | Biotech Hunter | Biotech Hunter